Estrogen Carcinogenesis in Breast Cancer

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 3, 2011, Pages 473-484

  Germain, Doris ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor; Knockout mice; Mammary gland development; Transcription factor

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; CYCLIN D1; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; REPRESSOR OF ESTROGEN RECEPTOR; STAT3 PROTEIN; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRANSCRIPTION FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULTHOOD; BIRTH; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CELL MEMBRANE; GENE AMPLIFICATION; HORMONAL CARCINOGENESIS; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; KNOCKOUT MOUSE; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUBERTY; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSGENIC MOUSE;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; ESTROGENS; FEMALE; HUMANS; MICE; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

MUS;

EID: 80052196450     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.05.009     Document Type: Review

References (68)

1. Yager J.D., Davidson N.E. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354(3):270-282.
2. Mueck A.O., Seeger H. Breast cancer: are oestrogen metabolites carcinogenic?. Maturitas 2007, 57(1):42-46.
3. Hennighausen L., Robinson G.W. Information networks in the mammary gland. Nat Rev Mol Cell Biol 2005, 6(9):715-725.
4. Silberstein G.B. Postnatal mammary gland morphogenesis. Microsc Res Tech 2001, 52(2):155-162.
5. Kumaresan P., Turner C.W. Effect of various hormones on mammary gland growth of ovariectomized rats. Proc Soc Exp Biol Med 1967, 125(2):556-558.
6. Flux D.S. The effect of adrenal steroids on the growth of the mammary glands, uteri, thymus and adrenal glands of intact ovariectomized and oestrone-treated ovariectomized mice. J Endocrinol 1954, 11(3):238-254.
7. Jensen E.V. On the mechanism of estrogen action. Perspect Biol Med 1962, 6:47-59.
8. Walter P., Green S., Greene G., et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A 1985, 82(23):7889-7893.
9. Greene G.L., Gilna P., Waterfield M., et al. Sequence and expression of human estrogen receptor complementary DNA. Science 1986, 231(4742):1150-1154.
10. Greene G.L., Press M.F. Structure and dynamics of the estrogen receptor. J Steroid Biochem 1986, 24(1):1-7.
11. Green S., Kumar V., Krust A., et al. Structural and functional domains of the estrogen receptor. Cold Spring Harb Symp Quant Biol 1986, 51(Pt 2):751-758.
12. Tremblay G.B., Tremblay A., Copeland N.G., et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol 1997, 11(3):353-365.
13. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996, 392(1):49-53.
14. Lubahn D.B., Moyer J.S., Golding T.S., et al. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 1993, 90(23):11162-11166.
15. Bocchinfuso W.P., Korach K.S. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 1997, 2(4):323-334.
16. Clarke R.B., Howell A., Potten C.S., et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57(22):4987-4991.
17. Zeps N., Bentel J.M., Papadimitriou J.M., et al. Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth. Differentiation 1998, 62(5):221-226.
18. Smith G.H. Label-retaining epithelial cells in mouse mammary gland divide asymmetrically and retain their template DNA strands. Development 2005, 132(4):681-687.
19. Curtis Hewitt S., Couse J.F., Korach K.S. Estrogen receptor transcription and transactivation: estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res 2000, 2(5):345-352.
20. Bocchinfuso W.P., Lindzey J.K., Hewitt S.C., et al. Induction of mammary gland development in estrogen receptor-alpha knockout mice. Endocrinology 2000, 141(8):2982-2994.
21. Korach K.S. Estrogen receptor knock-out mice: molecular and endocrine phenotypes. J Soc Gynecol Investig 2000, 7(Suppl 1):S16-S17.
22. Harris H.A. Estrogen receptor-beta: recent lessons from in vivo studies. Mol Endocrinol 2007, 21(1):1-13.
23. Krege J.H., Hodgin J.B., Couse J.F., et al. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 1998, 95(26):15677-15682.
24. Couse J.F., Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us?. Endocr Rev 1999, 20(3):358-417.
25. Forster C., Makela S., Warri A., et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A 2002, 99(24):15578-15583.
26. Palmieri C., Cheng G.J., Saji S., et al. Estrogen receptor beta in breast cancer. Endocr Relat Cancer 2002, 9(1):1-13.
27. Antal M.C., Krust A., Chambon P., et al. Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERbeta-null mutant. Proc Natl Acad Sci U S A 2008, 105(7):2433-2438.
28. Pearce S.T., Jordan V.C. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 2004, 50(1):3-22.
29. Ariazi E.A., Leitao A., Oprea T.I., et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther 2007, 6(11):2817-2827.
30. Liu Y., Gao H., Marstrand T.T., et al. The genome landscape of ERalpha- and ERbeta-binding DNA regions. Proc Natl Acad Sci U S A 2008, 105(7):2604-2609.
31. Pietras R.J., Szego C.M. Endometrial cell calcium and oestrogen action. Nature 1975, 253(5490):357-359.
32. Pietras R.J., Szego C.M. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 1977, 265(5589):69-72.
33. Migliaccio A., Di Domenico M., Castoria G., et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996, 15(6):1292-1300.
34. Nemere I., Farach-Carson M.C. Membrane receptors for steroid hormones: a case for specific cell surface binding sites for vitamin D metabolites and estrogens. Biochem Biophys Res Commun 1998, 248(3):443-449.
35. Kelly M.J., Levin E.R. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 2001, 12(4):152-156.
36. Li L., Haynes M.P., Bender J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A 2003, 100(8):4807-4812.
37. Yang S.H., Liu R., Perez E.J., et al. Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A 2004, 101(12):4130-4135.
38. Pedram A., Razandi M., Wallace D.C., et al. Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell 2006, 17(5):2125-2137.
39. Anzick S.L., Kononen J., Walker R.L., et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277(5328):965-968.
40. Torres-Arzayus M.I., Font de Mora J., Yuan J., et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004, 6(3):263-274.
41. Torres-Arzayus M.I., Zhao J., Bronson R., et al. Estrogen-dependent and estrogen-independent mechanisms contribute to AIB1-mediated tumor formation. Cancer Res 2010, 70(10):4102-4111.
42. Montano M.M., Ekena K., Delage-Mourroux R., et al. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci U S A 1999, 96(12):6947-6952.
43. Murphy L.C., Simon S.L., Parkes A., et al. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res 2000, 60(22):6266-6271.
44. Simon S.L., Parkes A., Leygue E., et al. Expression of a repressor of estrogen receptor activity in human breast tumors: relationship to some known prognostic markers. Cancer Res 2000, 60(11):2796-2799.
45. Mussi P., Liao L., Park S.E., et al. Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary gland. Proc Natl Acad Sci U S A 2006, 103(45):16716-16721.
46. Sherr C.J. D-type cyclins. Trends Biochem Sci 1995, 20(5):187-190.
47. Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev 1998, 8:28-35.
48. Bernards R. CDK-independent activities of D type cyclins. Biochim Biophys Acta 1999, 1424(2-3):M17-M22.
49. Neuman E., Ladha M.H., Lin N., et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 1997, 17:5338-5347.
50. Zwijsen R.M., Buckle R.S., Hijmans E.M., et al. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 1998, 12:3488-3498.
51. Zwijsen R.M., Wientjens E., Klompmaker R., et al. Cdk-independent activation of estrogen receptor by cyclin D1. Cell 1997, 88:405-415.
52. McMahon C., Suthiphongchai T., DiRenzo J., et al. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci U S A 1999, 96(10):5382-5387.
53. Sicinski P., Donaher J.L., Parker S.B., et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995, 82:621-630.
54. Fantl V., Stamp G., Andrews A., et al. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995, 9(19):2364-2372.
55. Brisken C., Ayyannan A., Nguyen C., et al. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell 2002, 3(6):877-887.
56. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411(6841):1017-1021.
57. Wang T., Cardiff R.D., Zukerberg L., et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369:669-671.
58. Stendahl M., Kronblad A., Ryden L., et al. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004, 90(10):1942-1948.
59. Jirstrom K., Stendahl M., Ryden L., et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin d1 gene amplification. Cancer Res 2005, 65(17):8009-8016.
60. Ishii Y., Waxman S., Germain D. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res 2008, 68(3):852-860.
61. Fuqua S.A., Wiltschke C., Zhang Q.X., et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 2000, 60(15):4026-4029.
62. Herynk M.H., Fuqua S.A. Estrogen receptor mutations in human disease. Endocr Rev 2004, 25(6):869-898.
63. Kohler M.F., Berkholz A., Risinger J.I., et al. Mutational analysis of the estrogen-receptor gene in endometrial carcinoma. Obstet Gynecol 1995, 86(1):33-37.
64. Levin E.R., Pietras R.J. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 2008, 108(3):351-361.
65. Witters L.M., Kumar R., Chinchilli V.M., et al. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 1997, 42(1):1-5.
66. Kunisue H., Kurebayashi J., Otsuki T., et al. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 2000, 82(1):46-51.
67. Nicholson R.I., Hutcheson I.R., Harper M.E., et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001, 8(3):175-182.
68. Liddle F.J., Alvarez J.V., Poli V., et al. Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants. Biochemistry 2006, 45(17):5599-5605.